GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sharps Technology Inc (NAS:STSS) » Definitions » LT-Debt-to-Total-Asset

STSS (Sharps Technology) LT-Debt-to-Total-Asset : 0.00 (As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Sharps Technology LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Sharps Technology's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.00.

Sharps Technology's long-term debt to total assets ratio stayed the same from Sep. 2023 (0.00) to Sep. 2024 (0.00).


Sharps Technology LT-Debt-to-Total-Asset Historical Data

The historical data trend for Sharps Technology's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sharps Technology LT-Debt-to-Total-Asset Chart

Sharps Technology Annual Data
Trend Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
- - - -

Sharps Technology Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Sharps Technology LT-Debt-to-Total-Asset Calculation

Sharps Technology's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=0/11.789
=

Sharps Technology's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )/Total Assets (Q: Sep. 2024 )
=0/11.254
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sharps Technology  (NAS:STSS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Sharps Technology LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Sharps Technology's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Sharps Technology Business Description

Traded in Other Exchanges
N/A
Address
105 Maxess Road, Suite 124, Melville, NY, USA, 11747
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes are designed to eliminate potentially infectious and accidental needlestick injuries.
Executives
Robert Michael Hayes director, officer: Chief Executive Officer 75 BROOKSHIRE DRIVE, YOUNGSVILLE NC 27596
Andrew R. Crescenzo officer: Chief Financial Officer C/O ENZO BIOCHEM, 527 MADISON AVENUE, NEW YORK NY 10022
Timothy James Ruemler director 3311 RIVERPARK CT., BENITA SPRINGS FL 34134
Alan R. Blackman director, officer: CIO and COO 11502 ROBLES DR. REPP PLACE, TEMPLE TERRACE FL 33617
Paul K Danner director
Soren Bo Christiansen director 4059 SPRING VALLEY ROAD, DOYLESTOWN PA 18902
Brenda Baird Simpson director 7336 PRAIRIE STAR COURT,, PARKER CO 80134
Jason L. Monroe director 14527 LINDALE ROSE LANE, HUMBLE TX 77379
Barry Boris Berler officer: CTO and Inventor 77 HERZL STREET, RAMAT GAN L3 5244352